| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3179835 | Actas Dermo-Sifiliográficas | 2015 | 10 Pages |
Abstract
Severe papulopustular rash and xerosis may be clinical predictors of good response to anti-EGFR therapy. Patients who develop a papulopustular rash should be treated promptly because suboptimal treatment of this and other adverse effects can lead to delays in taking the prescribed anti-EGFR dose or to interruption of therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
A. Jaka, A. Gutiérrez-Rivera, A. López-Pestaña, E. del Alcázar, J. Zubizarreta, S. Vildosola, M.A. Arregui, C. Sarasqueta, C. Lobo, A. Tuneu,